Cadrenal Therapeutics prices USD 3 million at-the-market private placement of shares, warrants

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc.

CVKD

0.00
  • Cadrenal Therapeutics priced an at-the-market private placement for 960,000 common shares or pre-funded warrants with series C-1 and C-2 warrants.
  • Gross proceeds expected at USD 3 million; warrant exercises could add about USD 5.8 million.
  • Combined purchase price set at USD 3.13 per share; both warrant series carry a USD 3 exercise price.
  • Net proceeds expected to extend cash runway into Q1 2027; full cash warrant exercise could extend runway into the second half of 2027.
  • H.C. Wainwright is sole placement agent; closing expected around July 1, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.